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Abstract
Background and Aims: Autologous haematopoietic stem cell transplantation [AHSCT] is a 
therapeutic option for patients with severe, treatment-refractory Crohn’s disease [CD]. The evidence 
base for AHSCT for CD is limited, with one randomised trial [ASTIC] suggesting benefit. The aim 
of this study was to evaluate safety and efficacy for patients undergoing AHSCT for CD in Europe, 
outside the ASTIC trial.
Methods: We identified 99 patients in the European Society for Blood and Marrow Transplantation 
[EBMT] registry, who were eligible for inclusion. Transplant and clinical outcomes were obtained 
for 82 patients from 19 centres in seven countries.
Results: Median patient age was 30 years [range 20–65]. Patients had failed or been intolerant to 
a median of six lines of drug therapy; 61/82 [74%] had had surgery. Following AHSCT, 53/78 [68%] 
experienced complete remission or significant improvement in symptoms at a median follow-up 
of 41 months [range 6–174]; 22/82 [27%] required no medical therapy at any point post-AHSCT. In 
patients who had re-started medical therapy at latest follow-up, 57% [24/42] achieved remission or 
significant symptomatic improvement with therapies to which they had previously lost response or 
been non-responsive. Treatment-free survival at 1 year was 54%. On multivariate analysis, perianal 
disease was associated with adverse treatment-free survival (hazard ratio 2.34, 95% confidence 
interval [CI] 1.14–4.83, p = 0.02). One patient died due to infectious complications [cytomegalovirus 
disease] at Day +56.
Conclusions: In this multicentre retrospective analysis of European centres, AHSCT was relatively 
safe and appeared to be effective in controlling otherwise treatment-resistant Crohn’s disease. 
Further prospective randomised controlled trials against standard of care are warranted.
Key Words:  Autoimmune disease; autologous haematopoietic stem cell transplant; Crohn’s disease
1. Introduction
Crohn’s disease [CD] is an immunologically mediated chronic disease 
characterised by episodic intestinal inflammation and dysregulation 
of the mucosa-associated immune system.1 Anti-inflammatory and 
immunosuppressive agents are the mainstay of therapy, but up to 
25% of patients remain refractory to optimal medical therapy, and a 
further 50% experience loss of response.2,3 Treatment-refractory CD 
is associated with adverse quality of life, recurrent hospitalisation, 
and increased mortality.4,5
Autologous haematopoietic stem cell transplantation [AHSCT] is 
a potential therapeutic option for treatment-refractory CD.6 AHSCT 
may lead to remission in CD by chemotherapy-mediated ablation of 
inflammatory cells followed by marrow reconstitution and restor-
ation of immune tolerance.7 The mechanisms underlying this process 
are incompletely defined, but thymic re-activation, broadening of the 
total T, B, NK cell, and plasma cell repertoire, and resetting of regu-
latory T cell function, have been suggested to play a role.8
Clinical experience of AHSCT for CD is limited, with several 
small series suggesting clinical benefits.9–18 In a Phase 1/2 study of 
24 patients with severe treatment-refractory CD, AHSCT resulted in 
clinical relapse-free survival of 91% at 1 year and 19% at 5 years, 
with a rapid and sustained improvement in Crohn’s Disease Activity 
Index [CDAI] post AHSCT.10 Only one randomised trial of AHSCT 
for CD [ASTIC] has been reported to date.19 This study enrolled 
patients with active CD not amenable to surgery and unresponsive 
to treatment with three or more immunosuppressive/biologic agents 
to AHSCT [n = 23] or control [mobilisation and AHSCT deferred 
for 1  year, n  =  22]. One patient died of sepsis and hepatic veno-
occlusive disease, and the trial failed to meet its primary endpoint 
of clinical and endoscopic ‘cure’ at 1 year, a composite of freedom 
from disease on imaging and endoscopy, CDAI < 150 and no active 
treatment for 3  months. This has been criticised for being overly 
stringent, and patients demonstrated sustained improvement on pre-
specified secondary endpoints.19,20
European Society for Blood and Marrow Transplantation 
[EBMT] guidelines, published in 2012, have included recommenda-
tions for AHSCT in CD types: i] active and unresponsive disease 
despite multiple lines of therapy; ii] extensive disease where surgical 
resection would expose the patient to small bowel syndrome risk; 
and iii] refractory colonic disease where a stoma is not acceptable to 
the patient.6 As the number of patients undergoing AHSCT in any 
centre to date are limited, multicentre studies are required. EBMT 
maintains a registry of all patients undergoing AHSCT for any indi-
cation, and provides a means to identify the total European cohort. 
We therefore designed this retrospective study to evaluate the clinical 
use and outcomes of all AHSCT in CD performed in EBMT trans-
plant centres outside the ASTIC trial.
2. Methods
2.1. EBMT registry
EBMT is a not-for-profit medical and scientific organisation that 
represents over 500 HSCT centres from over 50 countries. The 
EBMT registry now contains details on over 500 000 allogeneic and 
autologous transplants performed since 1986. All patients included 
in the registry give written consent before transplant for the collec-
tion and analysis of anonymised data. The data are maintained in the 
central EBMT registry in line with legal and regulatory requirements 
for data protection, confidentiality, and accuracy. EBMT implements 
regular quality assurance measures including ensuring centre ac-
creditation, regular cross-checks with national registries, annual sur-
veys, and regular audit processes. This study was performed in line 
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with EBMT guidelines and approved by the Autoimmune Diseases 
Working Party [ADWP].
2.2. Patient population
Patients who underwent AHSCT for Crohn’s disease were identified 
from the EBMT registry. All adult patients [aged ≥18 years at time 
of AHSCT] undergoing AHSCT for a primary diagnosis of CD from 
1997 to 2015 were eligible for inclusion. Patients who had partici-
pated in the ASTIC trial were excluded. From a total of 99 patients 
across 27 centres, data were obtained for 82 patients transplanted in 
19 centres in eight countries from 1996 to 2015[see Supplementary 
data available at ECCO-JCC online]. Data were unavailable for 17 
patients due to lack of response to repeated requests.
2.3. Study endpoints
Transplant and clinical outcomes for each patient were obtained dir-
ectly from the EBMT registry supplemented by a standardised ques-
tionnaire completed by the treating clinicians in each centre. The 
primary study endpoint was clinical disease response [defined below] 
assessed by the patient’s gastroenterologist 1 year following AHSCT, 
as compared with pre-mobilisation clinical status. Secondary end-
points included overall survival [OS], transplant-related mortality 
[TRM], treatment-free survival, and clinical disease response to 
mobilisation, at 100 days and at latest clinical assessment. Variables 
considered for descriptive analyses were medical/surgical ther-
apy pre- and post-AHSCT, disease extent and behaviour pre- and 
post-AHSCT, and neutrophil and platelet engraftment dates. Data 
on complications post-AHSCT were recorded, including infectious 
complications requiring hospitalisation [bacterial, viral, or fungal] 
up until 12 months post-AHSCT, and incidence of malignancy and 
secondary autoimmune disease post-AHSCT.
2.4. Definitions
Clinical disease response was categorised as:
• remission: no abdominal pain and normal stool frequency;
• improvement: improvement in abdominal pain and/or stool 
frequency;
• stable/no change: no appreciable improvement in abdominal 
pain and/or stool frequency;
• worse: deterioration in abdominal pain and/or stool frequency. 
The introduction, reduction, or withdrawal of steroids, immu-
nomodulators, or biologic therapy, and need for further surgical 
therapy, were also recorded.
Disease behaviour was assessed as stricturing, penetrating, both, 
or neither, pre- and post-AHSCT [Supplementary Table 2, available 
as Supplementary data at ECCO-JCC online]. Neutrophil engraft-
ment was defined as time from day of transplant until Day 1 of 3 
consecutive days with an absolute neutrophil count ≥0.5 x 10^9/L, 
whereas platelet engraftment was defined as time from day of 
transplant until Day 1 of 3 consecutive days with a platelet count 
≥20 x 10^9/L. Treatment- related mortality [TRM] was defined 
as any death after AHSCT within the first 100 days post-AHSCT. 
Treatment-free survival was defined as survival from transplantation 
without major surgery or medical therapy.
2.5. Statistics
Qualitative variables were described as percentage, continuous vari-
ables using median and range. Overall survival and treatment-free 
survival were calculated according to the method of Kaplan and 
Meier. Variables considered in univariate and multivariate analyses 
of disease response and treatment-free survival were recipient age at 
AHSCT [>/≤median], time from diagnosis to AHSCT [>/≤median], 
patient sex [male vs female], disease classification [limited vs exten-
sive without perianal disease vs extensive with perianal disease], 
disease behaviour [non-stricturing/non-penetrating vs stricturing vs 
penetrating], and pre-transplant smoking status. For treatment-free 
survival, a Cox proportional hazards model was used to evaluate the 
independent effect of covariates on outcome. A p-value of less than 
0.05 was considered significant. Statistical analyses were performed 
with SPSS 24 [SPSS Inc./IBM, Armonk, NY, USA] and R 3.4.0 [R 
Development Core Team, Vienna, Austria] software packages.
3. Results
3.1. Patient and disease characteristics
Patient and disease characteristics are summarised in Table 1. Median 
patient age was 30 years [range 20–65] and 52/82 [63%] were female. 
Median age at first diagnosis of CD was 17  years [range 2–53]. 
Details of previous therapies are outlined in Table 2. Patients were 
heavily pre-treated, having failed or been intolerant to a median of 
six previous lines of therapy [range 3–10]; 44/82 [54%] had received 
experimental therapy before AHSCT. This included participation in 
clinical trials of experimental immunosuppressants, faecal transplant, 
leukocytapheresis, or mesenchymal stem cell therapy. Previous sur-
gical treatment was common, with 61/82 [74%] of patients having 
undergone at least one operation. The median time from first diag-
nosis of CD to AHSCT was 12 years [range 1–26]. Median length of 
follow-up following AHSCT was 41 months [range 6–174].
3.2. AHSCT characteristics and haematological 
outcomes
AHSCT details are summarised in Table 3. All patients underwent 
mobilisation with cyclophosphamide, and peripheral blood stem 
Table 1. Patient and disease characteristics.
Characteristic n [%]
Patient sex [female/male] 52 [63%] F/30 [37%] M
Median age at AHSCT [yrs] 30 [20–65]
Median age at diagnosis [yrs] 17 [2–53]
Extra-intestinal involvement at diagnosis
 None 54 [67%]
 Joints+/-skin 15 [18%]
 Skin 5 [6%]
 PSC 2 [3%]
 Other 4 [5%]
Median time from diagnosis to AHSCT [yrs] 12 [1–26]
Disease classification at mobilisation
 Limited 35 [46%]
 Extensive without perianal disease 20 [26%]
 Extensive with perianal disease 21 [28%]
Disease behaviour at mobilisation
 Stricturing 17 [21%]
 Penetrating 8 [10%]
 Stricturing+penetrating 14 [17%]
 Non-stricturing/non-penetrating 42 [52%]
 Perianal 23 [28%]
Median follow-up [months] 41 [6–174]
F, female; M, male; yrs, years; AHSCT, autologous haematopoietic stem cell 
transplant; PSC, primary sclerosing cholangitis.
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cells were re-infused a median of 2  months [range 1–16] later. 
Patients received conditioning with cyclophosphamide 200  mg/kg 
and 69/82 [86%] underwent in vivo T cell depletion with anti-thy-
mocyte globulin [ATG]. The median dose of ATG was 7.5  mg/kg 
[range 2.0–10.0]. The median CD34+ dose infused was 5.4 [range 
2.4–40.6] x 10^6/kg. CD34+ selection of the autologous graft was 
performed in 11% of patients, and the remained were unmanipu-
lated. All patients engrafted successfully. Neutrophil and platelet 
engraftment both occurred at a median of Day 10 [range 6–22 and 
6–44, respectively]; 62% received post-transplant granulocyte col-
ony stimulating factor [G-CSF].
3.3. CD outcomes
One-year follow-up data were available for 76 patients [93%], as 
one patient died at 56 days and data unavailable for four patients; 
33/76 [43%] were in CR, 15/76 [20%] were reported as improved, 
13/76 [17%] were unchanged, and 15/76 [20%] had worsened.
At 100 days post AHSCT, data were available for 80 patients; 
51/80 patients [64%] were in clinical remission [CR]. A further 22/80 
[28%] reported improvement. For 4/80 [5%] there was no change in 
disease, and in 3/80 [4%] the disease worsened compared with base-
line. At latest follow-up, data were available for 78 patients; 34/78 
[44%] were in CR, 19/78 [24%] were improved, 13/78 [17%] were 
unchanged, and 12/78 [15%] had worsened [Figure 1].
Predictors of achieving clinical disease remission or disease response 
[either remission or improvement] at 1 year were evaluated. There was 
no statistically significant impact of age at diagnosis, age at AHSCT, 
pre-transplant smoking status, time from diagnosis to AHSCT, patient 
sex, previous surgery, disease classification, or disease extent on the 
likelihood of achieving remission or disease response at 1 year.
Treatment-free survival was 54.6% (95% confidence interval 
[CI] 43.8 - 65.5%) at 1 year, and 27% [95% CI 17–38%] and 22% 
[95% CI 11–33%] at 3 and 5 years, respectively. There were no sig-
nificant predictors of treatment-free survival identified on univariate 
analysis. On multivariate analysis, extensive disease with perianal 
disease was found to be an independent predictor for adverse treat-
ment-free survival with a hazard ratio of 2.34 [95% CI 1.14–4.83, 
p-value 0.02] [see Table 4 for results of multivariate analysis].
3.4. Mortality and complications
One patient died at Day +56 post-AHSCT due to CMV infection, 
sepsis, and multiorgan failure, i.e. a transplant-related mortality of 
1.2%. Another patient died at 7.99  years post-AHSCT from sep-
sis and multi-organ failure. In the year post-AHSCT, 22/82 [27%] 
developed an infection requiring treatment after AHSCT (9/82 [%] 
bacterial, 11/82 [12%] viral). Epstein-Barr virus [EBV] and CMV 
reactivation occurred in 5/82 [6%] and 3/82 [4%], respectively. 
There were no cases of fungal infection.
During follow-up post-AHSCT, a secondary autoimmune disease 
was reported in 9/82 [13%]. These included thyroid disease [5/82; 
6%], rheumatoid arthritis [2/82; 2%], and inflammatory disorders 
[enthesopathy, neuritis, myelitis].
New malignancy developed in 5/82 [6%, three cases of skin 
malignancy, one each of testicular and prostate cancer]. The median 
time to diagnosis was 40  months [range 38–105] after AHSCT; 
18/82 [23%] had other complications reported, which included drug 
effects [adrenal insufficiency secondary to corticosteroids; marrow 
toxicity presumed secondary to mercaptopurine] and late effects 
with uncertain links to AHSCT [hypertension, fibromyalgia, type 2 
diabetes mellitus].
Five patients successfully conceived after AHSCT, leading to the 
births of healthy infants.
3.5. Post-AHSCT treatment of Crohn’s disease
In all, 73% [60/82 patients followed up] resumed medical therapy 
for Crohn’s disease at a median of 10  months [range 1–79] after 
AHSCT. A total of 37% [30/82] required some form of surgery post-
AHSCT, of whom 21/82 [26%] underwent major gastrointestinal 
[GI] surgery [laparotomy, resection, or formation of a stoma] at a 
median of 26 months [range 6–87]. Stoma reversal was performed in 
4/82 [5%] patients post-HSCT due to disease regression.
Table 2. Previous therapies.
Details n [%]
Previous surgery 61 [74%]
 Ileostomy 18 [22%]
 Colostomy 5 [6%]
 Small bowel resection 24 [29%]
 Ileocaecal resection 27 [33%]
 Partial colectomy 14 [17%]
 Total colectomy 11 [13%]
 Proctectomy 6 [7%]
 Strictureplasty 11 [13%]
 Seton insertion 13 [16%]
 Other 17 [18%]
Previous lines of drug therapy 6 [3–10]
 Corticosteroids 82 [100%]
 Thiopurine 78 [98%]
 Methotrexate 66 [82%]
 Anti-TNF 81 [99%]
 Anti-integrin 16 [20%]
 Primary enteral nutrition 23 [28%]
 Experimental or other drugs 44 [54%]
  Experimental biological therapy [IL6/IL2/IL10/IL17/ 
CCR9/gamma IFN/HDAC inhibition]
10 [12%]
 Ustekinumab 8 [10%]
 Thalidomide 4 [5%]
 Anti-MAd-CAM 3 [4%]
 Faecal transplant 3 [4%]
 Cyclophosphamide 3 [4%]
 Mesenchymal stem cells 2 [2%]
 Leukocytapheresis 2 [2%]
 Other 9 [11%]
TNF, tumour necrosis factor.
Table 3. Autologous haematopoietic stem cell transplant [AHSCT] 
details.
Mobilisation regimen:
 Cyclophosphamide/G-CSF 72 [91%]
 G-CSF alone 2 [3%]
Conditioning regimen:
 Cyclophosphamide/ATG 69 [86%]
 Cyclophosphamide/CD34+ selection 9 [11%]
Median dose CD34+ [x 10^6/kg] 5.4 [2.4–40.6]
Median time to neutrophil engraftment /days 10 [6–22]
Median time to platelet engraftment /days 10 [1–44]
Engraftment 82 [100%]
G-CSF, granulocyte colony stimulating factor; ATG, anti-thymocyte 
globulin.
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At latest follow-up, 42/78 patients [54%] were on treatment. 
In patients who had re-initiated medical therapy at latest follow-
up, 24/42 [57%] achieved remission or significant symptomatic 
improvement with therapies (including anti-tumour necrosis factor 
[TNF] therapy in 19/24) to which they had previously lost response 
or been non-responsive.
4. Discussion
The principal finding of this retrospective survey using the EBMT 
registry is that AHSCT in patients with severe, treatment-refractory 
CD can induce complete remission or significant improvement in 
around two-thirds [68%] at long-term follow-up; 55% were alive 
and off all treatment at 1 year. In a multivariate analysis, extensive 
disease with perianal disease was associated with adverse treatment-
free survival. This is in keeping with the results of ASTIC, which 
demonstrated that patients with perianal disease or current smok-
ers had a higher incidence of complications following AHSCT.20 As 
such, patients with perianal disease should be considered to be at 
higher risk of complications and relapse requiring re-initiation of 
treatment. An appreciable minority of 27% remained off all ther-
apy until latest follow-up, and 57% of patients who recommenced 
medical therapy following AHSCT were re-sensitised to therapies to 
which they had previously been refractory.
Although AHSCT alone does not frequently result in cure or 
long-term remission, it appears to have profound benefit in this 
highly refractory and difficult to treat patient population, where dis-
ease control and associated quality of life are poor, and life expec-
tancy is reduced. Of note, chronic active CD treated with intense 
immunosuppressive regimens in the absence of AHSCT is also asso-
ciated with significant morbidity and increased mortality.21 This is 
the largest cohort of patients undergoing AHSCT for CD reported 
to date, and adds significantly to the evidence supporting its efficacy.
A further important finding of this study is that the safety of 
AHSCT in this population is similar to AHSCT for other common 
indications, such as myeloma and lymphoma, reflected by a trans-
plant-related mortality of 1.2%.7 There was one transplant-related 
death in our cohort, and a second patient died at 7.99 years; 28% 
developed an infection post-transplant, in keeping with transplant-
associated infective complications in other diseases. The three cases 
of skin cancer observed may be linked to the longstanding multi-
agent immunosuppression experienced by this patient cohort. 
Optimising supportive care and restricting AHSCT to experienced 
centres has been shown to help mitigate AHSCT risk.22,23
In accordance with the Joint Accreditation Committee-ISCT and 
EBMT [JACIE] requirements, all AHSCT procedures in Europe are 
reported to the EBMT registry. The majority of patients in this study 
were treated following the 2012 EBMT Guidelines, which formed 
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Figure 1. Clinical disease response. Percentage of patients in each clinical disease response category [remission, improvement, stable disease, and worsening] 
at 100 days, 1 year and latest follow-up [median 3.4 years].
Table 4. Results from multivariate analysis for treatment-free survival.
Variables HR CI p-Value
Age at HSCT > median [30 years] 0.81 0.41–1.57 0.53
Time from diagnosis to HSCT > median [141 months] 1.20 0.65–2.23 0.56
Female vs male 1.39 0.80–2.48 0.26
Disease classification Limited [ref] 1
Extensive with perianal disease 1.61 0.77–3.37 0.20
Extensive without perianal disease 2.34 1.14–4.83 0.02
Smoker pre-transplant 1.64 0.85–3.15 0.14
Disease behaviour [three classes] Non-stricturing/non-penetrating [ref] 1
Stricturing 1.11 0.56–2.21 0.76
Penetrating 0.61 0.28–1.32 0.21
HSCT, haematopioetic cell transplant; HR, hazard ratio; CI, confidence interval.
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the basis for patient selection and transplant technique.6 Through 
pan-European multicentre collaboration, we were able to obtain 
patient-level data, including long-term follow-up. As a retrospective 
evaluation, however, our study has intrinsic limitations. First, evalu-
ation of clinical response was performed retrospectively. However, to 
reduce the risk of recall bias, contemporaneous notes were reviewed 
in all cases. To ensure accurate information, data collection was 
performed by the patient’s treating gastroenterologist. Second, the 
categorisation of clinical response was necessarily broad, which is 
unlikely to fully reflect the spectrum of clinical disease response. We 
elected not to collect imaging, endoscopic, or biomarker outcomes, 
as these investigations were not performed in a systematic manner 
for all patients. Finally, data were not available on quality of life 
outcomes. Outcomes from a subset of 19 patients in this cohort have 
been previously reported in a single-centre study.17
ASTIC is the only randomised controlled trial of AHSCT for 
CD to date.19 The 1-year follow-up data of 40 transplant recipients 
in ASTIC provide further evidence of efficacy, with complete endo-
scopic healing occurring in 50% of patients, and 47% were judged 
free of disease on endoscopy and imaging at 1 year.20 There was also 
a significant improvement from baseline to 1 year after transplant 
across multiple clinical, quality of life, and endoscopic endpoints. 
Those who did relapse were re-sensitised to TNF therapy to which 
they had previously been refractory, as in our study.20 Single-centre 
studies with longer-term follow-up have reported that AHSCT does 
not offer indefinite remission and, as in our study, high rates of 
restarting medical therapy are observed.10,17 However, CD appears 
to be more responsive to therapy after AHSCT even where a clinical 
relapse occurs. Against this background, our findings lend support to 
a strategy of AHSCT with re-introduction of drug therapy to enable 
longer-term remissions in this complex patient cohort.
Recently, ECCO and EBMT have produced a collaborative update 
and review of the field, offering specific guidance on the clinical role 
of AHSCT and how it should be delivered.24 We propose that future 
CD patients undergoing AHSCT outside clinical trials are enrolled 
in a European registry study to ensure harmonisation of outcome 
assessment. Although our data suggest a complication rate similar to 
other indications for AHSCT, it must be recognised that AHSCT rep-
resents an intensive therapy with significantly higher short-term risks 
than conventional treatments for CD. Late effects are a risk both for 
AHSCT and more conventional immunosuppressive therapies, due 
to the cumulative burden of many intense lines of treatment in these 
complex patients, which even in the absence of AHSCT is associated 
with significant morbidity and increased mortality.21 Such late effects 
are broad in spectrum, affect many organ systems, and require system-
atic evaluation. Our current study highlights some of the issues, for 
example the skin cancers and secondary autoimmune disease.25 Long-
term follow-up of patients combined with prospective data collection 
should help to evaluate these risks post-AHSCT.
The mechanism of action of AHSCT in CD remains ill-defined. 
AHSCT has been shown to drive profound changes to the innate 
and adaptive immune system.7,26 First, cytotoxic chemotherapy in 
combination with T cell depletion ablates autoreactive effector cells 
that may have been refractory to previous immunosuppressive and 
biologic therapies. Next, the immune system regenerates with thymic 
reactivation and diversification of the T cell receptor repertoire. New, 
tolerant regulatory T cells traffic and suppress re-emergent autore-
active T effector cells. A small pilot study provides some evidence 
that the immunomodulatory effects of AHSCT apply in CD, with an 
increase in Foxp3+ T regulatory cells and a reduction in cytokine-
secreting effector cells.27 In CD, there may be additional effects from 
mobilisation and induction chemotherapy on the gastrointestinal 
mucosa, changes to the microbiome, and effects from G-CSF and 
antibiotics. It is likely that a combination of these factors underlies 
the disease response and regain of responsiveness to agents to which 
patients were previously refractory.
In conclusion, this study supports the safety and efficacy of AHSCT 
in patients with severe CD, yielding long-term clinical remissions in a 
patient cohort refractory to existing medical therapy. Important ques-
tions remain. These include defining parameters for selection of the 
patient subgroup most likely to respond to AHSCT, whether reduced-
intensity conditioning regimens could improve safety and reduce tox-
icity, and whether the effect of AHSCT can be optimised with early 
introduction of post-AHSCT maintenance therapy. Optimising sup-
portive care and restricting AHSCT to experienced centres is likely 
to help mitigate AHSCT risk.22 Additionally, greater insight into the 
mechanisms by which AHSCT induces self-tolerance may open the 
door to novel targeted therapies. Further randomised clinical studies 
are warranted to assess the role of AHSCT in this challenging disease.
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